{"id":"fumaric-acid-esters","_chembl":{"chemblId":"CHEMBL1200711","moleculeType":"Small molecule","molecularWeight":"687.06"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Fumaric acid esters","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:44:49.740430+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Fumaric Acid Esters","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T02:44:59.381256+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:45:07.223612+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:44:57.037719+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fumaric acid esters","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:44:57.936575+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200711/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:44:59.291125+00:00"}},"_dailymed":null,"aiSummary":"Fumaric acid esters, developed by University Hospital Muenster, are currently marketed for an unspecified primary indication. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The lack of detailed revenue data and key trial results poses a significant risk in assessing the drug's market performance and competitive landscape.","_scrapedAt":"2026-03-27T23:30:52.676Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Fumaric_acid","title":"Fumaric acid","extract":"Fumaric acid or trans-butenedioic acid is an organic compound with the formula HO2CCH=CHCO2H. A white solid, fumaric acid occurs widely in nature. It has a fruit-like taste and has been used as a food additive. Its E number is E297. The salts and esters are known as fumarates. Fumarate can also refer to the C4H2O2−4 ion (in solution). Fumaric acid is the trans isomer of butenedioic acid, while maleic acid is the cis isomer."},"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:45:07.224154+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT03331835","phase":"PHASE4","title":"A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-11-03","conditions":"Psoriasis Vulgaris","enrollment":210},{"nctId":"NCT01848028","phase":"","title":"PsoBest - The German Psoriasis Registry","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2008-01","conditions":"Psoriasis, Psoriatic-arthritis","enrollment":3500},{"nctId":"NCT05008549","phase":"NA","title":"A Study to Assess the Synergistic Effects of a Cranberry Beverage on Cognitive Function","status":"COMPLETED","sponsor":"Ocean Spray Cranberries, Inc.","startDate":"2021-07-26","conditions":"Attention, Mood","enrollment":25},{"nctId":"NCT02954081","phase":"","title":"APremilast After FumaRic Acid Ester Treatment","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-01-26","conditions":"Psoriasis","enrollment":687},{"nctId":"NCT02951533","phase":"PHASE3","title":"A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2016-12-12","conditions":"Psoriasis","enrollment":119},{"nctId":"NCT02634801","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-01-20","conditions":"Plaque Psoriasis","enrollment":162},{"nctId":"NCT02337426","phase":"PHASE1","title":"Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2015-02-13","conditions":"Adult Brain Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma","enrollment":12},{"nctId":"NCT02474082","phase":"PHASE3","title":"Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-04","conditions":"Psoriasis","enrollment":202},{"nctId":"NCT00254982","phase":"PHASE3","title":"Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":"Psoriasis","enrollment":593},{"nctId":"NCT00466817","phase":"PHASE3","title":"Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-06","conditions":"Cytomegalovirus Infection","enrollment":109},{"nctId":"NCT01321164","phase":"PHASE3","title":"Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2011-04","conditions":"Plaque Psoriasis","enrollment":30},{"nctId":"NCT01352988","phase":"PHASE2","title":"Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2011-07","conditions":"Lupus Erythematosus, Cutaneous","enrollment":11},{"nctId":"NCT01088165","phase":"PHASE4","title":"The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2010-05","conditions":"Psoriasis, Cardiovascular Diseases, Diabetes Mellitus, Type 2","enrollment":66},{"nctId":"NCT00811005","phase":"PHASE3","title":"Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2008-10","conditions":"Pustular Palmoplantar Psoriasis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACUTE MYOCARDIAL INFARCTION"},{"count":1,"reaction":"BOWEN^S DISEASE"},{"count":1,"reaction":"CHEST PAIN"},{"count":1,"reaction":"DRUG DOSE OMISSION"},{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"DYSPNOEA EXERTIONAL"},{"count":1,"reaction":"ERECTILE DYSFUNCTION"},{"count":1,"reaction":"FALL"},{"count":1,"reaction":"HEAD INJURY"},{"count":1,"reaction":"INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION"}],"crossReferences":{"chemblId":"CHEMBL1200711"},"_approvalHistory":[],"publicationCount":328,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fumaderm® initial","Fumaderm®","Fumaric acid"],"phase":"marketed","status":"active","brandName":"Fumaric acid esters","genericName":"Fumaric acid esters","companyName":"University Hospital Muenster","companyId":"university-hospital-muenster","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:45:07.224154+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}